Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CYT01B + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CYT01B||CYT-0851|CYT0851|CYT 0851||RAD51 Inhibitor 4||CYT01B (CYT-0851) is a small molecule that inhibits RAD51-mediated homologous recombination, leading to cell death (AACR Annual Meeting 2019, Abstract 2566).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 22||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CYT01B + Talazoparib||Preclinical - Cell culture||Actionable||In a preclinical study, CYT01B and Talzenna (talazoparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|